info Dear Friend;
Attached is a news release announcing the filing of a patent application for a new method to characterize the dynamic nature of heart function based upon our existing AI. Here is some background:
1. The current method to quantify heart function relies upon analysis of the heart when it is full of blood (diastole) and when it has completed its contraction phase and ejected the blood (systole). you will recognize this type of analysis when people quote blood press as 120/80 where the 120 is systole and thew 80 is diastole. However, the rae of change as the heart takes your blood pressure from 80 to 120 is also important information about the strength and health of your heart.
2. While current cardiac ultrasound system capture a video clip of the heart beating, the dynamic natureofo the heart is not quantified routinely. A beating heart presentation is at best is "eye candy’.
3. Because the VMS+ process builds a mathematical model of the heart chambers at systole and diastole, we have been also measuring heart function at these endpoints, but we can do so much more with the model.
4. We have been working with an advisory group of top cardiologists for about year now and have created a number of new measurements to characterize the dynamic function of the heart and visually present them for rapid analysis. It was time to patent these new measurements as we believe they will become standard parameters collected and used by cardiologists to better diagnose and treat their patients. We want to “own” this novel approach.
5. This patent along with the original patent and knowhow on KBR we licensed from UW and the patent filed on the new tracking system are protecting our products as well as building lasting value to the company. A strong IP portfolio is a hallmark of a successful biotech company and adds value when potential acquirers do their due diligence.
In other news, Torrey Hills, our IR firm conducted a question answer session last week. Here is the link if you want to view it.
https://youtu.be/vB9iLLbiing
As always, I thank you for your continued interest and support for Ventripoint as we continue our mission to improve cardiac diagnosis and treatment for everyone, worldwide and especially for children.